These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20233850)

  • 1. Assessing the amount of unscheduled screening ("contamination") in the control arm of the UK "Age" Trial.
    Kingston N; Thomas I; Johns L; Moss S;
    Cancer Epidemiol Biomarkers Prev; 2010 Apr; 19(4):1132-6. PubMed ID: 20233850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years.
    Moss S; Thomas I; Evans A; Thomas B; Johns L;
    Br J Cancer; 2005 Mar; 92(5):949-54. PubMed ID: 15726102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group.
    Moss S
    J Med Screen; 1999; 6(3):144-8. PubMed ID: 10572845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. False-positive results in the randomized controlled trial of mammographic screening from age 40 ("Age" trial).
    Johns LE; Moss SM;
    Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2758-64. PubMed ID: 20837718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
    Duffy SW; Mackay J; Thomas S; Anderson E; Chen TH; Ellis I; Evans G; Fielder H; Fox R; Gui G; Macmillan D; Moss S; Rogers C; Sibbering M; Wallis M; Warren R; Watson E; Whynes D; Allgood P; Caunt J
    Health Technol Assess; 2013 Mar; 17(11):vii-xiv, 1-95. PubMed ID: 23489892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.
    FH01 collaborative teams
    Lancet Oncol; 2010 Dec; 11(12):1127-34. PubMed ID: 21093374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials.
    de Koning HJ; Boer R; Warmerdam PG; Beemsterboer PM; van der Maas PJ
    J Natl Cancer Inst; 1995 Aug; 87(16):1217-23. PubMed ID: 7563167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tailored Breast Screening Trial (TBST)].
    Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
    Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.
    Moss SM; Cuckle H; Evans A; Johns L; Waller M; Bobrow L;
    Lancet; 2006 Dec; 368(9552):2053-60. PubMed ID: 17161727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammography in symptomatic and asymptomatic patients.
    Stomper PC; Gelman RS
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):611-40. PubMed ID: 2691492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated results of the Gothenburg Trial of Mammographic Screening.
    Bjurstam NG; Björneld LM; Duffy SW
    Cancer; 2016 Jun; 122(12):1832-5. PubMed ID: 27061821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammographic surveillance of asymptomatic breast cancer relatives in general practice: rate of re-attendance and GP- and patient-related barriers.
    Duijm LE; Guit GL; Zaat JO
    Fam Pract; 1997 Dec; 14(6):450-4. PubMed ID: 9476075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammography screening: A major issue in medicine.
    Autier P; Boniol M
    Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance.
    Brett J; Austoker J
    J Public Health Med; 2001 Dec; 23(4):292-300. PubMed ID: 11873891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures.
    Moss S; Waller M; Anderson TJ; Cuckle H;
    Br J Cancer; 2005 Mar; 92(5):955-60. PubMed ID: 15726103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammography screening after risk-tailored messages: the women improving screening through education and risk assessment (WISER) randomized, controlled trial.
    Bodurtha J; Quillin JM; Tracy KA; Borzelleca J; McClish D; Wilson DB; Jones RM; Quillin J; Bowen D
    J Womens Health (Larchmt); 2009; 18(1):41-7. PubMed ID: 19105686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of mammographic screening from age 40 ('Age' trial): patterns of screening attendance.
    Johns LE; Moss SM;
    J Med Screen; 2010; 17(1):37-43. PubMed ID: 20356944
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.